Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$10.53-1.13%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Corvus Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.214
Annual ending 2026-12-31
Revenue	—	1.18M
EPS	—	-0.748
Annual ending 2027-12-31
Revenue	—	3.79M
EPS	—	-0.929

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Fund operations into Q2 2028	Corvus plans to fund operations into Q2 2028.	Improving	fails to maintain funding through Q2 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage operating losses	A primary condition in Corvus Pharmaceuticals, Inc.'s published investment case. The stated target is operating loss does not exceed $14.88M.	Under Pressure	operating loss rises above $14.88M	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Market expectations for product success	A supporting condition in Corvus Pharmaceuticals, Inc.'s published investment case. The stated target is market expectations align with actual product success.	Improving	market expectations exceed actual product success	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.93

Unavailable → $-0.93 · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	Unavailable	3 / 4
2026-07-26	Unavailable	Unavailable	4 / 3
2026-07-27	Unavailable	Unavailable	3 / 4
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	Unavailable	4 / 3
2026-07-30	Unavailable	Unavailable	3 / 4
2026-07-31	Unavailable	$4,545,600	4 / 5
2026-08-01	$-0.87	Unavailable	5 / 3
2026-08-02	Unavailable	$4,545,600	4 / 5
2026-08-03	Unavailable	$4,545,600	4 / 5
2026-08-04	Unavailable	$4,545,600	4 / 5
2026-08-05	$-0.87	Unavailable	5 / 3
2026-08-06	Unavailable	$4,545,600	4 / 5
2026-08-07	$-0.87	Unavailable	5 / 3
2026-08-08	Unavailable	$4,545,600	4 / 5
2026-08-09	Unavailable	$4,545,600	4 / 5
2026-08-10	Unavailable	$4,545,600	4 / 5
2026-08-11	$-0.87	Unavailable	5 / 3
2026-08-12	Unavailable	$4,545,600	4 / 5
2026-08-13	Unavailable	$4,545,600	4 / 5
2026-08-14	$-0.87	Unavailable	5 / 3
2026-08-15	$-0.87	Unavailable	5 / 3
2026-08-16	$-0.87	Unavailable	5 / 3
2026-08-17	$-0.87	Unavailable	5 / 3
2026-08-18	$-0.87	Unavailable	5 / 3
2026-08-19	$-0.87	Unavailable	5 / 3
2026-08-20	$-0.93	Unavailable	5 / 3
2026-08-21	$-0.93	Unavailable	5 / 3
2026-08-22	$-0.93	Unavailable	5 / 3
2026-08-23	$-0.93	Unavailable	5 / 3
2026-08-24	$-0.93	Unavailable	5 / 3
2026-08-25	$-0.93	Unavailable	5 / 3
2026-08-26	$-0.93	Unavailable	5 / 3
2026-08-27	$-0.93	Unavailable	5 / 3
2026-08-28	$-0.93	Unavailable	5 / 3
2026-08-29	$-0.93	Unavailable	5 / 3
2026-08-30	$-0.93	Unavailable	5 / 3
2026-08-31	$-0.93	Unavailable	5 / 3
2026-09-01	$-0.93	Unavailable	5 / 3
2026-09-02	$-0.93	Unavailable	5 / 3
2026-09-03	$-0.93	Unavailable	5 / 3
2026-09-04	$-0.93	Unavailable	5 / 3
2026-09-05	$-0.93	Unavailable	5 / 3
2026-09-06	$-0.93	Unavailable	5 / 3
2026-09-07	$-0.93	Unavailable	5 / 3
2026-09-08	$-0.93	Unavailable	5 / 3
2026-09-09	$-0.93	Unavailable	5 / 3
2026-09-10	$-0.93	Unavailable	5 / 3
2026-09-11	$-0.93	Unavailable	5 / 3
2026-09-12	$-0.93	Unavailable	5 / 3
2026-09-13	$-0.93	Unavailable	5 / 3
2026-09-14	$-0.93	Unavailable	5 / 3
2026-09-15	$-0.93	Unavailable	5 / 3
2026-09-16	$-0.93	Unavailable	5 / 3
2026-09-17	$-0.93	Unavailable	5 / 3
2026-09-18	$-0.93	Unavailable	5 / 3
2026-09-19	$-0.93	Unavailable	5 / 3
2026-09-20	$-0.93	Unavailable	5 / 3
2026-09-21	$-0.93	Unavailable	5 / 3
2026-09-22	$-0.93	Unavailable	5 / 3
2026-09-23	$-0.93	Unavailable	5 / 3
2026-09-24	$-0.93	Unavailable	5 / 3
2026-09-25	$-0.93	Unavailable	5 / 3
2026-09-26	$-0.93	Unavailable	5 / 3
2026-09-27	$-0.93	Unavailable	5 / 3
2026-09-28	$-0.93	Unavailable	5 / 3
2026-09-29	$-0.93	Unavailable	5 / 3
2026-09-30	$-0.93	Unavailable	5 / 3
2026-10-01	$-0.93	Unavailable	5 / 3
2026-10-02	$-0.93	Unavailable	5 / 3
2026-10-03	$-0.93	Unavailable	5 / 3
2026-10-04	$-0.93	Unavailable	5 / 3
2026-10-05	$-0.93	Unavailable	5 / 3
2026-10-06	$-0.93	Unavailable	5 / 3
2026-10-07	$-0.93	Unavailable	5 / 3
2026-10-08	$-0.93	Unavailable	5 / 3
2026-10-09	$-0.93	Unavailable	5 / 3
2026-10-10	$-0.93	Unavailable	5 / 3
2026-10-11	$-0.93	Unavailable	5 / 3
2026-10-12	$-0.93	Unavailable	5 / 3
2026-10-13	$-0.93	Unavailable	5 / 3
2026-10-14	$-0.93	Unavailable	5 / 3
2026-10-15	$-0.93	Unavailable	5 / 3
2026-10-16	$-0.93	Unavailable	5 / 3
2026-10-17	$-0.93	Unavailable	5 / 3
2026-10-18	$-0.93	Unavailable	5 / 3
2026-10-19	$-0.93	Unavailable	5 / 3
2026-10-20	$-0.93	Unavailable	5 / 3
2026-10-21	$-0.93	Unavailable	5 / 3
2026-10-22	$-0.93	Unavailable	5 / 3
2026-10-23	$-0.93	Unavailable	5 / 3
2026-10-24	$-0.93	Unavailable	5 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	7	0	0
2026-07-01	8	0	0
2026-08-01	8	0	0
2026-09-01	8	0	0
2026-10-01	8	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Fund operations into Q2 2028Direct metric needs a verified mapping
Manage operating lossesPublished status: Under Pressure
Market expectations for product successDirect metric needs a verified mapping

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-63.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Corvus Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The thesis is on watch: management is advancing soquelitinib trials and has funding guidance into the second quarter of 2028, but recent financial performance is weak and confidence in the evidence is low.

What's priced into Corvus Pharmaceuticals, Inc.

The snapshot gives no valuation or market-expectations evidence, so whether the shares look cheap or expensive and what the market already assumes cannot be assessed. The financing supports operations, but it does not remove the risk that ongoing losses and trial uncertainty weigh on the thesis.

What the fundamentals likely do

Near term, losses and cash burn remain elevated as clinical work expands, despite management being on track with its funding-runway priority. The August earnings miss and a high-miss-rate industry make the next report a risk to watch; the evidence does not establish a clear path to improved financial performance. Over the multi-year view, progress depends on clinical development, including Phase 3 PTCL and Phase 2 atopic dermatitis trials.

What Corvus Pharmaceuticals, Inc. hinges on

A guidance cut on the next call would be a negative signal, while continued delivery on trial plans and the stated funding runway would support the thesis. A weakening jobs trend could add pressure to sector sentiment, while strong results and guidance from healthcare bellwethers could provide a sector tailwind. The snapshot does not show clinical trial outcomes, so their progress and eventual results remain key uncertainties.